 | |
 | |
| Combination of | |
|---|---|
| Amlodipine | Calcium channel blocker |
| Valsartan | Angiotensin II receptor antagonist |
| Clinical data | |
| Trade names | Exforge, Copalia, Dafiro |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| (verify) | |
Amlodipine/valsartan, sold under the brand name Exforge among others, is a blood pressure lowering combination drug. It contains amlodipine, as the besilate, a dihydropyridine-type calcium channel blocker, and valsartan, an angiotensin II receptor antagonist. [6] This combination is usually well tolerated and effective for the reduction of blood pressure. [7]
The combination was approved for medical use in the European Union in January 2007, [3] and in the United States in June 2007. [8]
The combination is also available with hydrochlorothiazide. [9] [10] It was approved for medical use in the United States in April 2009, [11] and in the European Union in November 2009. [12] [13] [14]
